Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.

Journal article

BACKGROUND: Low-dose aspirin is of definite and substantial net benefit for many people who already have occlusive vascular disease. We have assessed the benefits and risks in primary prevention. METHODS: We undertook meta-analyses of serious vascular events (myocardial infarction, stroke, or vascular death) and major bleeds in six primary prevention trials (95,000 individuals at low average risk, 660,000 person-years, 3554 serious vascular events) and 16 secondary prevention trials (17,000 i...

Expand abstract

Authors: Baigent, C; Blackwell, L; Collins, R; Emberson, J; Godwin, J

• Publication status: Published
• Peer review status: Peer reviewed
• Publisher: Elsevier Publisher's website
• Publication date: 2009-05-28
• DOI: 10.1016/s0140-6736(09)60503-1
• EISSN: 1474-547X
• ISSN: 0140-6736
• Language: English
• Keywords: Practice Guidelines as Topic; Primary Prevention; Male; Research Design; Cardiovascular Diseases; Antithrombotic Trialists' (ATT) Collaboration; Sex Distribution; Cause of Death; Randomized Controlled Trials as Topic; Risk Reduction Behavior; Risk Assessment; Aspirin; Hemorrhage; Risk Factors; Secondary Prevention; Female; Humans; Fibrinolytic Agents; Treatment Outcome; Patient Selection